[The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease].
The main aim of the study was the evaluation of the efficacy and drug safety of cerepro (choline alfoscerate) used for treating outpatients with cerebrovascular disease. Ninety patients with cerebrovascular disease, who had motor, coordination, emotional and cognitive disturbances were enrolled in the study. Sixty patients of the group 1 had stroke, 30 patients (group 2) had chronic ischemic brain disease. All patients received basic therapy (antihypertensive, antiaggregant or anticoagulant, cholesterol-lowering drugs). Cerepro was administrated in combined therapy according to the scheme: 1000 mg cerepro (in 200 ml of the 0.9% NaCl solution) once a day intravenously in drops during 10 days; then 1200 mg daily per os during 6 weeks. We assessed the dynamic of neurological symptoms and restoration of lost functions (MMSE, Feeling-activity-mood test, HDRS, GCI). The results indicate the efficacy of cerepro in outpatients with chronic cerebrovascular disease and stroke. It was demonstrated that cerepro led to improvement of coordination neurological symptoms, cognitive and emotional functions, activity and mood in patients of both groups. Clinical effect was higher in patients after stroke. Cerepro was well tolerated.
E V
EV
Kostenko
L V
LV
Petrova
I Iu
IIu
Artemova
T V
TV
Vdovichenko
P A
PA
Ganzhula
A M
AM
Ismailov
L N
LN
Lisenker
S V
SV
Petrov
O V
OV
Otcheskaia
L D
LD
Rotor
A A
AA
Khozova
A N
AN
Boĭko
D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D005997:Glycerylphosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D005997:Glycerylphosphorylcholine